Ticker
Reporting Basis
Period
From
To
Form Type
Report Format
Update Type


LIGAND PHARMA-B   FYE=12 (December)

Annual - Income Statement - Company Specific

Fiscal period2020201920182017201620152014201320122011
Period End Date12/31/202012/31/201912/31/201812/31/201712/31/201612/31/201512/31/201412/31/201312/31/201212/31/2011
Revenues : Product sales--------------------
Contract revenue42.6641.8293.77--------------
Revenues : Royalties33.8046.98128.5688.6959.4238.1929.9923.5814.079.21
Revenues : Sale of royalty rights, net--------------------
Revenues:Material sales------22.0722.5027.6628.4919.079.4312.12
Captisol109.9631.4929.12--------------
Revenues : Collaborative research and development and other revenues------30.3527.056.066.066.327.888.70
Total Revenues186.42120.28251.45141.10108.9771.9164.5448.9731.3930.04
Cost of Products Sold------5.375.575.819.145.733.604.91
Contract manufacturing--------------------
Cost of Captisol30.4211.356.34--------------
Amortization of intangibles23.4416.8615.7912.1210.642.382.38------
Research and development59.3955.9127.8626.8921.2211.019.759.2710.7910.29
Write-off of acquired in-process research and development--------------0.480.002.28
General and Administrative64.4441.8837.7328.6527.6525.4022.5717.9815.7814.58
Lease termination costs------------(1.08)(0.56)(1.02)(0.55)
Write-off of acquired technology--------------------
Co-promotion--------------------
Accretion of deferred gain on sale leaseback------------------1.70
Gain from sale of Promacta license--812.80----------------
Gain from sale of Vernalis R&D17.11------------------
Total Operating Expenses177.69126.0087.7373.0365.0944.5944.9134.0331.2032.62
Operating income25.85807.08163.7368.0843.8927.3319.6314.940.19(0.88)
Interest expense27.4235.7548.2813.4612.8411.804.862.082.922.30
Gain on deconsolidation of Viking Therapeutics, Inc----------28.190.000.00----
Gain (loss) from short-term investments(16.93)1.0550.38--------------
Equity in net losses from Viking Therapeutics------(2.05)(23.13)(5.14)0.00------
Interest income8.0828.4314.002.060.66----------
Other, net(0.11)(4.17)(6.50)2.60(0.62)1.771.67(0.06)0.520.63
Debt conversion expense--------------------
Decrease in liability for contingent value rights----------(5.01)(5.14)(3.60)(1.65)(1.01)
Pro-rata non-cash net losses of Viking Therapeutics, Inc--------------0.00----
Total other (expense) income, net(36.38)(10.44)9.60(10.85)(35.93)8.00(8.32)(5.74)----
Income (loss) from continuing operations before income taxes(10.54)796.64173.3357.237.9635.3311.309.21(3.87)(3.56)
Deferred benefit: Federal(15.67)74.6329.9344.0810.53(167.41)0.410.40(0.91)(10.80)
Deferred benefit : State(3.38)0.20(0.19)0.23(0.24)(24.72)(0.03)(0.06)(0.30)(3.13)
Income tax benefit from continuing operations(7.55)167.3430.0144.6810.33(192.12)0.410.37(1.19)(13.27)
Current Benefit : Federal10.8989.47----0.020.010.020.000.000.52
Current Benefit : State0.593.100.420.110.010.010.020.030.020.14
Current Benefit : Foreign0.02(0.07)(0.16)0.26------------
Income from continuing operations including noncontrolling interests--------------8.83----
Loss from continuing operations--------(2.37)227.4410.898.83(2.67)9.71
Income from Discontinued Operations--------0.730.000.002.592.150.00
Discontinued operations : Income (loss) from discontinued operations before income taxes--------------------
Discontinued operations : Gain on sale of AVINZA Product Line before income taxes----------------3.66--
Discontinued operations : Gain (loss) on sale of Oncology Product Line before income taxes--------1.140.000.00----0.00
Discontinued operations : Income tax benefit (expense) on discontinued operations--------(0.41)------(1.51)--
Loss before cumulative effect of a change in accounting principle--------------------
Cumulative effect of changing method of accounting for variable interest entity--------------------
Net income(2.99)629.30143.3212.56----10.8911.42(0.53)--
Net loss attributable to noncontrolling interests----------(2.38)(1.13)------
Net Income (loss) Available to Common Shareholders(2.99)629.30143.3212.56(1.64)229.8212.0211.42(0.53)9.72
EPS (Basic) : Loss from continuing operations--------(0.11)11.610.590.43(0.14)0.49
EPS (Basic) : Income (loss) from discontinued operations--------0.04--0.000.130.110.00
EPS (Basic) : Cumulative effect of changing method of accounting for variable interest entity--------------------
Net Earnings Per Share (Basic)(0.18)33.136.770.60(0.08)11.610.590.56(0.03)0.49
EPS (Diluted) : Loss from continuing operations--------(0.11)10.830.560.43(0.14)0.49
EPS (Diluted) : Income (loss) from discontinued operations--------0.04--0.000.120.110.00
EPS (Diluted) : Cumulative effect of changing method of accounting for variable interest entity--------------------
Net Earnings Per Share (Diluted)(0.18)31.855.960.53(0.08)10.830.560.55(0.03)0.49
Weighted Average Shares Outstanding (Basic)16.1919.0021.1621.0320.8319.7920.4220.3119.8519.66
Weighted Average Shares Outstanding (Diluted)16.1919.7624.0723.4820.8321.2321.4320.7519.8519.71